Core Viewpoint - The company has received acceptance for its marketing authorization applications for BA6101 and BA1102 in the UK, indicating a significant step in expanding its product portfolio in the international market [1][2]. Group 1: Product Information - BA6101 is a biosimilar to Prolia, approved in China in 2022, and is aimed at treating osteoporosis in postmenopausal women and men at high risk of fractures, as well as bone loss in prostate cancer patients undergoing hormone therapy [1]. - BA1102 is a biosimilar to Xgeva, approved in China in 2024, targeting the prevention of skeletal-related events in adults with advanced malignancies and the treatment of giant cell tumors of bone [2]. Group 2: Market Potential - The global market for denosumab, represented by Prolia and Xgeva, is projected to generate approximately $6.6 billion in sales in 2024, highlighting the substantial commercial opportunity for the company's products [2]. - The company is actively pursuing international clinical trials and regulatory submissions for BA6101 and BA1102 to enhance their global market presence, including applications to EMA, FDA, and PMDA [2]. Group 3: Quality Assurance - The company has established a comprehensive quality management system that meets international standards to support the successful commercialization of denosumab and future biopharmaceuticals [2].